Aemetis - AMTX Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMTX, but not buy additional shares or sell existing shares.
View AMTX analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1-year price targets for Aemetis' shares. Their AMTX share price forecasts range from $3.00 to $27.00. On average, they predict the company's share price to reach $13.05 in the next year. This suggests a possible upside of 379.8% from the stock's current price.
View analysts price targets for AMTX or view top-rated stocks among Wall Street analysts.

Aemetis' stock was trading at $3.96 at the beginning of 2023. Since then, AMTX shares have decreased by 31.3% and is now trading at $2.72.
View the best growth stocks for 2023 here.

Aemetis saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 7,590,000 shares, an increase of 10.6% from the February 28th total of 6,860,000 shares. Based on an average daily trading volume, of 560,300 shares, the short-interest ratio is presently 13.5 days.
View Aemetis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our AMTX earnings forecast.

Aemetis, Inc. (NASDAQ:AMTX) announced its quarterly earnings results on Thursday, November, 11th. The specialty chemicals company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.25. The specialty chemicals company had revenue of $49.90 million for the quarter, compared to analyst estimates of $54.23 million. During the same period last year, the company earned ($0.59) EPS.

Strategy Shares Halt Climate Change ETF holds 278 shares of AMTX stock, representing 0.08% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Tilly's (TLYS), Auxly Cannabis Group (CBWTF), Novan (NOVN), Aeterna Zentaris (AEZS), American Cannabis (AMMJ) and Bionano Genomics (BNGO).

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Aemetis' stock is owned by many different retail and institutional investors. Top institutional investors include Encompass Capital Advisors LLC (5.08%), Alliancebernstein L.P. (4.90%), Millennium Management LLC (2.87%), Geode Capital Management LLC (1.67%), Morgan Stanley (1.48%) and Thomist Capital Management LP (1.37%). Insiders that own company stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends.

Shares of AMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMTX stock can currently be purchased for approximately $2.72.

Aemetis (NASDAQ:AMTX) has a market capitalization of $99.69 million and generates $256.51 million in revenue each year. The specialty chemicals company earns $-107,760,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.

The company employs 158 workers across the globe.

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The official website for the company is www.aemetis.com. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at investors@aemetis.com, or via fax at 408-252-8044.